Tagged Articles

Eli Lilly 34 articles

Three drug makers reach tentative settlement in testosterone side effects MDL

Three manufacturers of testosterone replacement therapies among several in a multidistrict litigation accusing the companies of failing to warn consumers about cardiovascular risks with their products, have notified an Illinois federal judge that they have reached a tentative deal to settle the cases in which they are named. U.S. District Judge Matthew Kennelly told the manufacturers – Endo Pharmaceuticals Inc., Auxilium Pharmaceuticals LLC and GlaxoSmithKline LLC – that he would place a 45-day stay on the cases against them while the details of the settlement are worked out. He also told the remaining defendants – including AbbVie Inc., and Actavis ... Read More

Global sales of testosterone replacement therapies expected to decline

Market research company Technavio is predicting that the global testosterone replacement therapy market will decline at a compound annual growth rate of more than 3 percent during the period 2016 to 2020, with a decline rate of close to 15 percent in the Americas, where sales are predicted to fall from $2 billion to $0.9 billion by 2020. Technavio’s report reviewed market outlook and growth prospects for the global testosterone replacement market during that time period, taking into consideration revenue generated from sales of branded and generic drugs that treat and prevent hypogonadism (low testosterone levels) and revenues to be generated ... Read More

Testosterone side effects likely to hamper sales

The risk of cardiovascular events has hampered sales of testosterone replacement therapies, and numerous studies providing evidence of adverse events associated with the synthetic hormones are causing many people to look at the products in a negative light. These are just some barriers manufacturers of testosterone treatments face in the near future, an analyst with Transparency Market Research (TMR) predicts. Sales of testosterone replacement therapies have boomed in recent years with new formulations and brands entering the market, each pushing products through heavy direct-to-consumer marketing campaigns. The companies have even coined the phrase “Low T,” and suggested to men that ... Read More

Many newer diabetes drugs carry cancer risks

Within the past two decades, thanks in large part to diabetes experts lowering the blood sugar threshold, millions more Americans were labeled as diabetic and became eligible for medication to help regulate blood sugar levels. As a result, the diabetes drug industry boomed. Sales of diabetes drugs topped $23 billion, more than the revenues generated from the National Football League, Major League Baseball, and the National Basketball Association combined. But in the past decade, a Milwaukee Journal Sentinel and MedPage Today investigation discovered that none of the 30 new diabetes drugs were proven to improve diabetics’ risk for associated health ... Read More

New Jersey man blames heart attack on Axiron testosterone treatment

New Jersey resident Patrick Miller was 54 when he started using Axiron, a testosterone replacement product used to treat men who have low levels of the hormone in their blood. A month later, on Oct. 3, 2012, he had a heart attack. Thirteen months later, the Journal of the American Medical Association (JAMA) published a study that found men who used testosterone treatments have a 30 percent increased risk of having a heart attack, stroke or dying. And, in January 2014, the journal PLOS One found a two-fold increased risk of heart attack among older men in the first 90 days ... Read More

Takeda faces damning testimony in Actos bladder cancer lawsuit

Upjohn Co. allegedly backed out of development of the type 2 diabetes drug Actos in 1993 because of safety concerns, according to court testimony. However, Takeda Pharmaceuticals, the drug’s maker, urged Upjohn to say that it was backing away from the project because it didn’t believe the drug would be effective in the treatment of diabetes, an expert witness for the plaintiffs said. Randall Tackett, a pharmacologist and toxicologist at the University of Georgia, testified on behalf of plaintiff Frances Wisniewski, who is suing Takeda over claims that the Japanese drug maker’s diabetes medication Actos caused her to develop bladder cancer, ... Read More

Erectile dysfunction drug Strenda given new ‘fast acting’ status by FDA

Auxillium and Vivus’ erectile dysfunction drug Strenda has been granted a new designation by the Food and Drug Administration (FDA) that may help it compete against the dominating pills in the market, Pfizer’s Viagra and Eli Lilly’s Cialis. Strenda has been granted “fast-acting” status, allowing the pill to be taken just 15 minutes before sex, instead of 30 minutes as previously stated on its label. Comparatively, Cialis must be taken daily while Viagra must be taken one to two hours before sex. Strendra contains the active ingredient avanafil, which is in a class of drugs called phosphodiesterase inhibitors. Other drugs in ... Read More

Drug companies fight request for more information linking diabetes drugs to pancreatic cancer

A number of drug companies are fighting a request to produce documents involving reports linking pancreatic cancer to use of their type 2 diabetes treatments. Defendants Merck Sharp & Dohme Corp., Eli Lilly, Novo Nordisk, and Amylin Pharmaceuticals told a California federal court that gathering the requested information would be an “unreasonably burdensome fishing expedition.” Plaintiffs already have adverse events reports but are now seeking source files including underlying medical records of individual patients used to compile the reports. The motion is the most recent development in a multidistrict litigation against the drug companies that manufacture and distribute a newer ... Read More

Judge refuses to throw out $9 billion judgment against Actos makers

A Louisiana federal judge refused to throw out a $9 billion judgment against Takeda Pharmaceuticals and Eli Lilly & Co., alleging the companies hid bladder cancer risks with its blockbuster type 2 diabetes drug Actos. The April verdict was in favor of plaintiffs Terrence and Susan Allen, who claimed the drug companies withheld from doctors and patients information about bladder cancer risks associated with Actos. It was the first U.S. trial of its kind, setting the stage for thousands of other similar lawsuits against Takeda and Eli Lilly involving Actos and bladder cancer. Japan-based Takeda was ordered to pay $6 billion ... Read More

European drug regulators approve new type 2 diabetes treatment

European drug regulators have approved Eli Lilly and Boehringer Ingelheim’s new Type 2 diabetes drug epagliflozin, which will be marketed under the brand name Jardiance. The once-daily tablet is designed to reduce blood sugar levels by blocking glucose reabsorption in the kidneys and remove excess glucose through the urine. Unlike other diabetes treatments, Jardiance does not rely on a patient’s insulin levels in order to be effective. Jardiance is in a class of Type 2 diabetes drugs known as sodium glucose co-transporter 2 (SGLT-2) inhibitors. Other drugs in this class include Canagliflozin, which was the first in the class to ... Read More